Therapy Areas: Autoimmune
CEL-SCI Presents New Data for Its LEAPS Vaccine in the Treatment of Rheumatoid Arthritis at the American Association of Immunologists 103rd Annual Meeting
17 May 2019 - - US-based CEL-SCI Corp.'s (NYSE American: CVM) senior vice president of research, cellular immunology Daniel Zimmerman, Ph.D. has presented new LEAPS data at the American Asso...
Vedanta Biosciences Closes Extended USD 45.5m Series C Financing
16 May 2019 - - US-based clinical-stage company Vedanta Biosciences has raised an additional USD 18.5m as an extension of its Series C financing, bringing the total for the round to USD 45.5m, the com...
Noveome Biotherapeutics Publishes Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cells
15 May 2019 - - US-based biopharmaceutical company Noveome Biotherapeutics, Inc has published preclinical results for ST266, its proprietary, cell-free platform biologic, published in the Journal...
Clover Biopharmaceuticals Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in China
10 May 2019 - - Chinese biotechnology company Clover Biopharmaceuticals has received Clinical Trial Application approval from the Chinese National Medical Products Administration to conduct clinical t...
Amerigen wins US FDA approval for generic Penicillamine in 250 mg capsules
10 May 2019 - Pharmaceutical group Amerigen Pharmaceuticals Limited reported on Friday the receipt of the US Food and Drug Administration's final approval for its Abbreviated New Drug Application...
Vedanta Biosciences Key Microbiome Patent Upheld in European Opposition Proceedings
9 May 2019 - - The Opposition Division of the European Patent Office has upheld US-based clinical-stage company Vedanta Biosciences' foundational patent EP2575835, strengthening Vedanta's in...
Related Headlines

Amerigen Pharmaceuticals Limited wins US FDA approval for Penicillamine Capsules USP in 250 mg

Xencor Doses First Patient in Phase 1 Study of XmAb23104 for the Treatment of Patients with Advanced Solid Tumors

Molgradex Received Fast Track Designation by FDA for Treatment of Autoimmune Pulmonary Alveolar Proteinosis

Can-Fite Prepares for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson

US FDA approves first ever paediatric treatment for Lambert-Eaton myasthenic syndrome

TetraGenetics Names Taunton-Rigby, Baron and Grau to its Board of Directors

Axial Biotherapeutics Presents New Preclinical Data from AB-2004 Program Demonstrating Reduction of Microbiome-Derived Metabolites in Mouse Models with Autism Spectrum Disorder at the International Society for Autism Research (INSAR) 2019 Annual Meet

Magenta Therapeutics Launches Proposed Public Offering

Concert Pharmaceuticals Names Høiland to its Board of Directors

Adaptive Biotechnologies Names Baldo as Chief Medical Officer

Tiziana Reports Encouraging Interim Clinical Data from an Ongoing Phase 2a Clinical Trial with Milciclib in Patients with Advanced Liver Cancer

GSK wins US FDA priority review approval for the intravenous (IV) formulation of Benlysta in children with lupus

First Subjects Dosed in Phase 1 Clinical Trial of MGTA-145, a First-Line Stem Cell Mobilization Product Candidate

AbbVie wins US FDA clearance for SKYRIZI to treart moderate to severe plaque psoriasis in adults

Alpine Immune Sciences Names Peng as President, Head of Research and Development